Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression

被引：0

作者：

Rosenberg, J. ^{[1
]}

Necchi, A. ^{[2
]}

Sweis, R. F. ^{[3
]}

Nakajima, K. ^{[4
]}

Lu, C. ^{[5
]}

Nogai, H. ^{[6
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA

[2] Ist Nazl Tumori Milano Fdn IRCCS, Med Oncol, Milan, Italy

[3] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA

[4] Bayer HealthCare Pharmaceut, Clin Dev, Whippany, NJ USA

[5] Bayer HealthCare Pharmaceut, Clin Stat, Whippany, NJ USA

[6] Bayer AG, Oncol, Berlin, Germany

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

925TiP

引用

页码：329 / 329

页数：1

共 50 条

[1] Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.
Rosenberg, Jonathan E.
Gajate, Pablo
Morales-Barrera, Rafael
Lee, Jae-Lyun
Necchi, Andrea
Penel, Nicolas
Zagonel, Vittorina
Sierecki, Mitchell Robert
Bao, Weichao
Zhou, Yinghui
Ellinghaus, Peter
Sweis, Randy F.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.
Rosenberg, Jonathan E.
Gajate, Pablo
Morales-Barrera, Rafael
Lee, Jae-Lyun
Necchi, Andrea
Penel, Nicolas
Zagonel, Vittorina
Sierecki, Mitchell Robert
Piciu, Ana-Maria
Ellinghaus, Peter
Sweis, Randy F.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial
Sweis, Randy F.
Gajate, Pablo
Morales-Barrera, Rafael
Lee, Jae-Lyun
Necchi, Andrea
de Braud, Filippo
Penel, Nicolas
Gruenwald, Viktor
Maruzzo, Marco
Meran, Johannes
Ishida, Tatiane Cristine
Bao, Weichao
Zhou, Yinghui
Ellinghaus, Peter
Rosenberg, Jonathan E.
JAMA ONCOLOGY, 2024, 10 (11) : 1565 - 1570
[4] Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
O'Donnell, Peter H.
Milowsky, Matthew I.
Petrylak, Daniel P.
Hoimes, Christopher J.
Flaig, Thomas W.
Mar, Nataliya
Moon, Helen H.
Friedlander, Terence W.
McKay, Rana R.
Bilen, Mehmet A.
Srinivas, Sandy
Burgess, Earle F.
Ramamurthy, Chethan
George, Saby
Geynisman, Daniel M.
Bracarda, Sergio
Borchiellini, Delphine
Geoffrois, Lionnel
Rey, Jose Pablo Maroto
Ferrario, Christiano
Carret, Anne-Sophie
Yu, Yao
Guseva, Maria
Moreno, Blanca Homet
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) : 4107 - +
[5] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Balar, Arjun V.
Galsky, Matthew D.
Rosenberg, Jonathan E.
Powles, Thomas
Petrylak, Daniel P.
Bellmunt, Joaquim
Loriot, Yohann
Necchi, Andrea
Hoffman-Censits, Jean
Perez-Gracia, Jose Luis
Dawson, Nancy A.
van der Heijden, Michiel S.
Dreicer, Robert
Srinivas, Sandy
Retz, Margitta M.
Joseph, Richard W.
Drakaki, Alexandra
Vaishampayan, Ulka N.
Sridhar, Srikala S.
Quinn, David I.
Duran, Ignacio
Shaffer, David R.
Eigl, Bernhard J.
Grivas, Petros D.
Yu, Evan Y.
Li, Shi
Kadel, Edward E., III
Boyd, Zachary
Bourgon, Richard
Hegde, Priti S.
Mariathasan, Sanjeev
Thastrom, AnnChristine
Abidoye, Oyewale O.
Fine, Gregg D.
Bajorin, Dean F.
LANCET, 2017, 389 (10064): : 67 - 76
[6] Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study
Masuda, Norikazu
Iwata, Hiroji
Aogi, Kenjiro
Xu, Yihuan
Ibrahim, Ayman
Gao, Ling
Dalal, Rita
Yoshikawa, Reigetsu
Sasaki, Yasutsuna
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (12) : 1088 - 1094
[7] PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
Huddart, Robert A.
Siefker-Radtke, Arlene O.
Balar, Arjun, V
Bilen, Mehmet A.
Powles, Thomas
Bamias, Aristotelis
Castellano, Daniel
Khalil, Maged F.
van der Heijden, Michiel S.
Koshkin, Vadim S.
Pook, David W.
Ozguroglu, Mustafa
Santiago, Linda
Zhong, Bob
Chien, David
Lin, Wei
Tagliaferri, Mary A.
Loriot, Yohann
FUTURE ONCOLOGY, 2020, 17 (02) : 137 - 149
[8] Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression
Sternberg, C. N.
Bellmunt, J.
Nishiyama, H.
Petrylak, D. P.
Quinn, D. I.
Nakajima, K.
Lu, C.
Holynskyj, A.
ANNALS OF ONCOLOGY, 2018, 29 : 331 - 331
[9] Safety lead-in of phase II SBRT and durvalumab with or without tremelimumab for unresectable and cisplatin-ineligible, locally advanced or metastatic bladder cancer.
Kundu, Palak
Lee, Alan
Drakaki, Alexandra
Liu, Sandy
Shen, John
Chin, Arnold I.
Chamie, Karim
Chang, Albert
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[10] Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Vuky, Jacqueline
Balar, Arjun V.
Castellano, Daniel
O'Donnell, Peter H.
Grivas, Petros
Bellmunt, Joaquim
Powles, Thomas
Bajorin, Dean
Hahn, Noah M.
Savage, Mary J.
Fang, Xiao
Godwin, James Luke
Frenkl, Tara L.
Moreno, Blanca Homet
de Wit, Ronald
Plimack, Elizabeth R.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2658 - +

← 1 2 3 4 5 →